EDIT — Editas Medicine Income Statement
0.000.00%
Last trade - 00:00- $246.98m
- $140.40m
- $32.31m
Annual income statement for Editas Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 90.7 | 25.5 | 19.7 | 78.1 | 32.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 226 | 219 | 246 | 247 | 283 |
| Operating Profit | -135 | -193 | -226 | -169 | -251 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -116 | -193 | -220 | -153 | -237 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -116 | -193 | -220 | -153 | -237 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -116 | -193 | -220 | -153 | -237 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -116 | -193 | -220 | -153 | -237 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.98 | -2.85 | -3.21 | -2.02 | -2.73 |